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ABSTRACT  
Captopril is an angiotensin converting enzyme (ACE) 
inhibitor as  antihypertensive treatment with half-life about 2h. 
Development of sustained-release dosage form can maintenance 
the drug concentration at therapeutic window in long period of 
time with constant release. Montmorillonite, zeolite and 
hydrotalcite nano-composites were used as drug carrier as 
sustained release dosage form. This study aimed to determine the 
drug release from nanocomposite of montmorillonite-drug, zeolite-
drug and hydro-talcite-drug. Nanocomposite drug and carriers 
were made with the model drug was dispersed in carrier with 
matrix system. Matrices used montmorillonite, zeolite and 
hydrotalcite with concentrations of 20%, 30% and 40%. 
Characterization of matrices were done by testing the physical 
properties of the granules and drug release. Dissolution test using 
apparatus II USP model with speed rotation of 50rpm of, 900mL of 
HCl 0.1N as medium. The results were compared statistically with 
one way ANOVA 95% of interval confidence. The results showed 
that the difference of matrices and concentrations gave the 
difference effect in flow time, compact-tibility, DE360, initial burst 
release and maintenance release (p<0.05). Nanocomposites 
between drug and nanoclays occurred after 60min were shown 
with decreasing the drug release rate. Nanocomposite was formed 
with the drug molecules adsorb on nanoporous of carrier material. 
Increasing of clays concentration improved the fluidity and 
compactibility, reduced the drug release. 
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INTRODUCTION 
Captopril is a first active orally 
angiotensin converting enzyme inhibitor, the 
enzyme responsible to inhibits the formation of 
angiotensin II effectively for hypertensive 
treatment (Donald et al., 1982). Given orally, 
captopril is absorbed rapidly, has a 
bioavailability of 75%. Peak concentration in 
plasma occur within an hour, and a half-life of 
about 2h. The oral dose of captopril ranges 
from 6.25 to 150mg twice  or three times daily 
(Brunton et al., 2008). Strategy in development 
of sustained release dosage form to maintain 
drug at therapeutic levels in the long term. 
Captopril sustained release dosage form is 
considered to provide benefits by reducing the 
frequency of drug administration, improve the 
patient compliance. Therefore the effectiveness 
of treatment can be achieved and reduce the 
side effect (Collet and Moreton, 2002). 
Montmorillonite, zeolite and hydrotalcite 
are one type of natural clays. Montmorillonite 
consist of large layer and insoluble cation are 
bound weakly to the space between the layer 
(Wijaya et al., 2004). Clays have three properties 
(swelling ability, cation/anion exchange and 
intercalation), with the abilities were developed 
as nano carriers of nanocomposite drug-clays 
for controlled release drug delivery (Hua et al., 
2010; Zheng et al., 2007). Montmorillonite have 
average porous size (nanoporous) of about 15 
Å (1.5nm) (Figure 1) which was called basal 
spacing (Ainurofiq et al., 2010). Nanocomposite 
drug-clays naturally occur drug to be loaded 
into the nanoporous as nanocomposite (Suresh 
et al., 2010).  The  natural  montmorillonite  and 
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Figure 1. XRD pattern of natural mont-
morillonit with basal spacing 1.5 nm 
 
pillarization of montmorillonite with various 
molecular weight of chitosan (small, medium, 
and high) could release the drug slowly from 
dosage form using a poorly soluble drug 
(theophylline) (Ainurofiq et al., 2010). 
Zeolite have cavity (porous) smaller than 
mesoporous material, and these characteristics 
can be used to achieve the more effective 
controlled release drug delivery. Pore size of 
nanoporous and mesoporous materials as the 
host determine the size of the drug molecules 
to be adsorbed into the pore. Adsorption and 
release of the molecules in the matrix is 
controlled by size selectivity. The pore size can 
provide better controlled drug release 
(Gonzales et al., 2013). The nanocomposite of 
drug-zeolite, the composite combined with 
biodegradable polymers (chitosan, gelatin, and 
alginate) and the drug loaded in the 
nanoporous of zeolite provided prolong drug 
release (Zhang et al., 2007). 
Hydrotalcite (anionic clays) or layered 
double hydroxides are two dimensional 
material, these material is natural hydrotalcite 
with the brucite structure, where for each set of 
eight Mg2+ cation, two are substituted by Al3+. 
The positive charge in excess is balanced by 
carbonate anions hosted together with water 
molecules in the interlayer (Cavani et al., 1991). 
The intercalation of these anions clays, and 
their high affinity to carbonate ion to                 
acid dissolution is able to the loaded drug in   
the interlayer. The composite between            
drug (ketoprofen, sodium diclofenac, and 
chloramphenicol succinate) and hydrotalcite, 
the drug release slowly up to 24h (San Roman et 
al., 2013). 
This study aimed to determine the           
drug release (kinetic models and characteristics) 
from nanocomposite of nanoclays (zeolite, 
hydrotalcite and montmorillonite) with 
dispersion in matrix system using captopril as 
water soluble drug from sustained release tablet 
dosage form. 
 
MATERIAL AND METHODS 
Captopril (Afine Chemicals, China), 
lactose (DFE Pharma, Germany), nature 
montmorillonite from Wonosegoro,           
Boyolali, Central Java, nature zeolite from 
Gunung Kidul, Yogyakarta, magnesium stearate  
(Bratachem, Indonesia), hydrotalcite (Sigma 
Aldrich, Singapore), hydrocloric acid p.a 
(Merck, Germany), K3[Fe(CN)6] p.a (Merck, 
Germany), FeCl3 p.a (Merck, Germany), 
demineralized water. 
 
Purification of montmorillonite 
Montmorillonite had been purified from 
bentonite, coarse bentonite, were washed with 
demineralized water. The colloid phase was 
precipitated over night and dried in oven at 
temperature of 110°C and rewashed three 
times. Montmorillonite were sieved with 180 
mesh sieve. 
 
Purification of zeolite 
Zeolite were washed with demineralized 
water, and the colloid phase were precipitated 
for one night. The sediment were then over 
rewashed three times The residue were dried in 
oven at temperature of 100°C for 6h followed 
by refluxed with 500mL of HCl 0.1N and for 
5h at temperature 90°C. The resulted material 
were washed with demineralized water until the 
neutral pH. Zeolite, eventually it was washed 
with 500mL of NaOH 0.75N to build the ratio 
proportion of silica and aluminum followed by 
demineralized water until the neutral pH. The 
precipitate were dried at 110°C for 6h. The 
dried zeolite were sieved with 180 mesh sieve. 
 
Preparation of captopril tablet 
Tablets were formulated according to 
Table I. Wet granulation method was employed 
for formulation. All of the component in 
formula except lubricant (1% magnesium 
stearate) were mixed in the mixer for 16min 
25rpm followed by addition of demineralized 
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water to the blend until elastic mass of wet 
granules. Mass of wet granules were sieved with 
16 mesh sieve. Wet granules were dried in oven 
at 40°C for 6h. The dried granules were mixed 
with magnesium stearate in mixer for 4min 
25rpm. The granules were characterized by 
particle size distribution test with analytical 
sieving, moisture content, bulk density and 
tapped density. The mass of tablets were 
characterized by fluidity and compact-tibility 
test. The compactibility test was done with the 
deepness of upper punch of 5.3mm and the 
lower punch of 8.15 mm. 
The tablet compression process, the 
weight of tablet was arranged at 250mg and the 
hardness was controlled at 10-12kg. 
 
Drug release 
Drug release was determined using 
dissolution tester type apparatus II (paddle 
method), where 900mL of HCl 0.1N was  used 
as dissolution medium maintained at 
37±0.05°C at 50rpm for 6h. Aliquots of 10mL 
were withdraw at 15, 30, 45, 60, 90, 120, 180, 
240, 300, and 360min with replacement of         
10mL of the fresh media. All the samples           
were analyzed directly at 202.4nm (λmax of 
captopril) using UV-Vis Hitachi U-2900 
spectrophotometer. 
 
Drug release kinetics 
Drug release kinetics is assumed to 
reflect different release mechanism of 
controlled release matrix system. Therefore, six 
kinetic models were applied to analyze the drug 
release data to find the best fitting equation. 
These models are zero-order release, first-order 
release, Hixcon-Crowell, Weibull, Higuchi 
release and Korsmeyer-Peppas. The release 
mechanism based on the exponential diffusion 
value (n) of Korsmeyer Peppas equation. The 
best fitting equation based on coefficient of 
determination (R2), AIC (Akaike’s Information 
Criterion) and RMSE (root mean square eror).  
 
Analysis of result 
The results obtained were analyzed 
statistically, with normal distribution followed 
by one way ANOVA with 95% of confidence 
interval, if significant different followed by t-
LSD test. The drug releases were computed by 
free open source software, KinetDS® (Mendyk 
et al., 2012). 
 
RESULT AND DISCUSSION 
According on the results of physical 
properties tablet mass (Table II), granule using 
matrix montmorillonit showed the best physical 
properties tablet mass between zeolite and 
hydrotalcite, by fluidity and compactibility. 
Increasing matrix concentration enhanced the 
physical properties of captopril granules. 
Granules have good fluidity if flow time of 
100g of granules not more than 10s  and the 
angle of repose is less than 30° (Fudholi, 1983). 
The fluidity was influenced by some factor such 
as moisture content, granules density, particle 
size distribution, porosity and cohesiveness 
interparticulate. The particle size distribution 
characteristic showed that fines (particle size 
less than 180µm) in granules not should be 
more than 10%.  
Table I. Composition formula of captopril tablet 
 
Formula 
Composition(mg) 
Captopril Zeolit Hydrotalcite Montmorillonite Lactose Mg stearat 
F1 50 - - - 197.5 2.5 
F2 50 50 - - 147.5 2.5 
F3 50 75 - - 122.5 2.5 
F4 50 100 - - 97.5 2.5 
F5 50 - 50 - 147.5 2.5 
F6 50 - 75 - 122.5 2.5 
F7 50 - 100 - 97.5 2.5 
F8 50 - - 50 147.5 2.5 
F9 50 - - 75 122.5 2.5 
F10 50 - - 100 97.5 2.5 
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Good flowability will produce uniform dosage 
form with constant filling granules in the 
compression room. The compactibility was 
showed by the tablet hardness after 
compaction, higher of compactibility of mass 
tablet then mass of tablet to be compressed 
with low pressure. Uniformity of dosage form 
was determined by the drug content of 
captopril tablet. Uniformity of dosage form as 
required in Indonesian Pharmacopecia IV, that 
the drug content not less than 85% and not 
more than 115% with the relative standard 
deviation not more than 6%. The controlled 
hardness of tablet was expected that the 
hardness will not affect the drug release form 
dosage form. Tablet without matrix showed 
that the hardness was not in accordance with 
the prescribed. Low compactibility and low of 
the moisture content caused tablet capping 
when compressed with high pressure and 
cannot formed compact mass with hardness of 
10-12kg. Hardness of tablet without matrix 
with the maximum pressure without occurrence 
of capping and lamination. 
Drug release profile (Figure 2) showed 
that the drug release form of captopril 
sustained release tablet dosage form. In the 
initial release  occurred initial burst release or 
the drug release uncontrolled, the matrices 
cannot control the drug release and the drug 
cannot loaded in the nanoporous of clays 
maximally. 
Composite between drugs and clays were 
formed maximally at 60 min that showed the 
lower drug release rate. Nanocomposites were 
formed with the drug molecules adsorb on 
nanoporous of carrier materials (zeolite, 
hydrotalcite and montmorillonite), then the 
loaded drug in the nanoporous have  hydrogen 
bonding interaction between the drug molecules 
and nanoclays making the drug release slowly.   
Clay   materials  are naturally occurring  
Table II.  Physical properties of captopril tablets mass (mean±SD) 
 
Formula 
Bulk density 
(g/mL) 
Tapped density 
(g/mL) 
moisture 
content (%) 
flow time 
(sec) 
Compact-
tibility (kg) 
angle of 
repose (o) 
fines 
(%) 
F1 0.629±0.01 0.731±0.01 0.50±0.00 5.08±0.38 1.28±0.16 24.90±0.81 3.08±0.29 
F2 0.667±0.01 0.709±0.02 1.80±0.17 6.26±0.11 5.18±0.53 24.00±1.24 3.15±0.86 
F3 0.658±0.01 0.721±0.01 2.30±0.00 5.02±0.12 6.08±0.46 24.20±1.45 4.60±0.82 
F4 0.658±0.02 0.727±0.01 2.00±0.00 4.16±0.09 6.65±0.82 25.40±0.89 3.68±0.71 
F5 0.538±0.00 0.581±0.01 1.20±0.17 5.40±0.21 3.94±0.45 26.15±0.35 2.89±0.23 
F6 0.602±0.00 0.694±0.00 1.33±0.29 4.57±0.07 5.97±0.48 24.88±0.28 2.79±1.46 
F7 0.704±0.00 0.848±0.00 2.00±0.50 5.29±0.16 6.70±0.68 24.70±0.49 6.45±1.82 
F8 0.667±0.00 0.767±0.01 1.00±0.00 5.07±0.22 7.24±0.19 24.43±1.52 3.12±1.04 
F9 0.816±0.00 0.984±0.00 1.00±0.00 4.13±0.24 10.31±0.74 22.96±0.40 0.33±0.06 
F10 0.800±0.00 0.948±0.04 1.30±0.58 3.65±0.13 13.25±0.92 20.86±0.59 1.08±0.90 
 
Tabel III. Physical properties of captopril tablet and the release rate (mean±SD) 
 
Formula 
Hardness 
(kg) 
Drug content  
(%) 
DE360  
(%) 
Initial burst release 
(mg/min) 
Maintenance 
release (mg/min) 
F1 4.52±0.28 96.29±2.85 90.64±3.42 0.8802±0.0083 0.0058±0.0019 
F2 10.15±1.19 99.19±1.07 83.90±2.15 0.6274±0.0270 0.0319±0.0109 
F3 10.21±0.23 100.85±4.34 74.15±1.61 0.4486±0.0114 0.0646±0.0052 
F4 10.42±0.57 97.99±3.96 56.59±5.76 0.3356±0.0414 0.0552±0.0037 
F5 11.46±0.78 96.92±4.33 81.22±2.26 0.5928±0.0594 0.0361±0.0058 
F6 10.98±0.72 96.29±4.23 68.34±2.90 0.4319±0.0253 0.0598±0.0105 
F7 10.44±0.98 101.88±3.11 69.62±3.82 0.4049±0.0251 0.0665±0.0063 
F8 11.39±0.74 99.43±0.86 68.96±5.48 0.5702±0.0564 0.0296±0.0023 
F9 11.32±0.78 98.58±1.14 65.62±3.04 0.4352±0.0189 0.0455±0.0031 
F10 11.54±0.65 100.00±1.22 60.64±0.90 0.4175±0.0145 0.0431±0.0047 
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cationic/anionic exchangers and so they may 
undergo in exchange with basic drug in 
solution. Release rate of the drug decreased 
with enhancement of the matrix 
concentrations. 
F4 showed the lowest drug release rate, 
and F7 showed the fastest between the other 
formulas. The drug release showed the 
exponential/parabolic curve showed by the β 
(shape parameter of Weibull’s equation) <1, 
there are indicated that the initial release with 
higher slope in the initial. The drug release 
using 2 release models were initial burst release 
occurred at 0 until 60min and maintenance 
release that occurred at 60-360 min. 
Dissolution profile all formulas were compared 
with dissolution efficiency until 360 minutes 
(DE360), initial burst release and maintenance 
release. The result showed significant different 
with value of DE360 (p<0.05), initial burst 
release (p<0.05) and maintenance release 
(p<0.05). Release rate was determined by the 
profile pharmacokinetics approach of captopril 
with the rate of maintenance release more than 
0.02mg/min and approach the steady state 
concentration (0.05mg/min) and the lowest  
initial burst release rate. Montmorillonit 40% 
has been required the lowest of initial burst 
release rate and the expected of 
pharmacokinetics profile approach (steady 
state). The release mechanism based on 
diffusion exponential of Korsmeyer-Peppas 
equation. The exponential (n) equation was 
determined the release mechanism, fickian 
diffusion (n=0.45), anamolius transport 
(0.45<n<0.89), case II transport (n=0.89), and 
super case II transport (n>0.89) (Colombo et 
al. 2007). The mechanism release all formula 
showed that the mechanism release not 
followed the Korsmeyer-Peppas equation. 
Exponential value less than 0.45, the 
mechanism of release was unclassified. The 
mechanism release using 2 model of drug 
release because the nanocomposite of drug and 
clays, the composites were not occurred in the 
initial time. The best kinetic models to describe 
the release kinetics and fitting the equation 
based on goodness of fitting that the highest of 
coefficient determination (R2), the lowest of 
AIC, and the lowest of RMSE that showed the 
similarity between observed data and predicted 
data (equation model) (Motulsky & 
Chirtopoulos, 2003). The release kinetic was 
described by the Weibull’s model. The drug 
release linear relation can be obtained for a log-
log  plot of –ln (1-m) versus time (t) (Costa and 
Lobo, 2001). Ketoprofen, sodium diclofenac 
and chloramphenicol succinate loaded in the 
mesoporous of anionic clays (hydrotalcite) 
showed  the  initial  burst  release  in 1h and the  
 
 
Figure 2. The drug release profile of captopril from dosage form ( ___ : without matrix, ___ : zeolite, 
___ : hydrotalcite, ___ : montmorillonite, ■ : concentration 20%, ▲: concentration 30%, and ●: 
concentration 40%) 
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diffusional release mechanism (San Roman et 
al., 2013). The nanocomposites of ofloxacin 
with montmorillonite-chitosan reduced the 
initial burst release and the kinetic release 
followed the Higuchi equation and first-order 
kinetic (Hua et al., 2010). 
 
CONCLUSION 
Montmorillonite, zeolite and hydrotalcite 
were used as matrices captopril tablet could 
release the drug form dosage form with the 
sustained release with initial burst release and 
maintenance release. Montmorillonit 40% as 
matrix showed that the lowest initial burst 
release and expected maintenance release. 
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